1-4 of 4
Juliana Biondo
Close
Sort by
Journal Articles

Real-World Assessment of Second Primary Malignancies in a Treated and Untreated Chronic Lymphocytic Leukemia Population in the United States

Sikander Ailawadhi, Arliene Ravelo, Carmen Ng, Bonny Shah, Rongrong Wang, Katherine Eakle, Juliana Biondo
Journal: Blood
Blood (2022) 140 (Supplement 1): 8040–8041.
https://doi.org/10.1182/blood-2022-158139
Published: 2022
Journal Articles

Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments

Arliene Ravelo, Kelley Myers, Robyn Brumble, Cooper Bussberg, Brian Koffman, Beenish S. Manzoor, Juliana Biondo, Carol Mansfield
Journal: Blood
Blood (2022) 140 (Supplement 1): 10803–10805.
https://doi.org/10.1182/blood-2022-159648
Published: 2022
Journal Articles

Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD PhD, Matthew S Davids, Julie Chang, Shuo Ma, MD PhD, Juliana Biondo, Mehrdad Mobasher, MD MPH, Yong Mun, PhD, Anthony R Mato, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5556.
https://doi.org/10.1182/blood-2018-99-116942
Published: 2018
Journal Articles

Patterns of Ibrutinib Use, Discontinuation, and Hospitalization Among Patients with Chronic Lymphocytic Leukemia (CLL) in a US Healthcare Claims Database

Tu My To, PhD MPH, Wei-Shi Yeh, PhD MS, Juliana Biondo, Anthony S Masaquel, PhD MPH
Journal: Blood
Blood (2018) 132 (Supplement 1): 5909.
https://doi.org/10.1182/blood-2018-99-112679
Published: 2018